Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro

Journal of Immunotherapy

Volumn 20, Issue 4, 1997, Pages 276-286

  Kim, Christina J ^a   Prevette, Tracy ^a   Cormier, Janice ^a   Overwijk, Willem ^a   Roden, Matthew ^a   Restifo, Nicholas P ^a   Rosenberg, Steven A ^a   Marincola, Francesco M ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CTL; Dendritic cells; MART 1; Melanoma; Melanoma associated antigens; Pox viruses; Viral vectors

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; HLA A ANTIGEN; MELANOMA ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 3; RECOMBINANT INTERLEUKIN 4;

ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; POXVIRUS; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; VIRUS INFECTION;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CELLS, CULTURED; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNODOMINANT EPITOPES; MELANOMA; NEOPLASM PROTEINS; POXVIRIDAE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031464143     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199707000-00004     Document Type: Article

References (65)

1. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
2. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
3. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
4. Wolfel T, Van Pel A, Brichard V, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994;24:759-64.
5. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-65.
6. Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp 100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995;55:4972-9.
7. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37-44.
8. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996;56:4749-57.
9. Vitiello A, Ishioka G, Grey HM, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995;95:341-9.
10. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-96.
11. Grabbe S, Beissert S, Schwarz T, Granstein RD. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? [see comments]. Immunol Today 1995;16:117-21.
12. Steinman RM, Lustig DS, Conn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. 3. Functional properties in vivo. J Exp Med 1974;139:1431-45.
13. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973;137:1142-62.
14. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-5.
15. Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995;182:255-60.
16. + T cells. J Immunol 1995;154:4915-23.
17. + T lymphocytes to peptide antigen in vivo. J Immunol 1993;151:6742-50.
18. Inaba K, Metlay JP, Crowley MT, Steinman RM. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ [published erratum appears in J Exp Med 1990;172:1275]. J Exp Med 1990;172:631-40.
19. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products [see comments]. J Exp Med 1995;182:389-400.
20. + T cells and process soluble antigen. J Immunol 1995;155:5427-35.
21. Becker Y. Dendritic cell activity against primary tumors: an overview. In Vivo 1993;7:187-91.
22. Reid CD, Stackpoole A, Tikerpae J. TNF and GM-CSF dependent growth of an early progenitor of dendritic Langerhans cells in human bone marrow. Adv Exp Med Biol 1993;329:257-62.
23. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992;360:258-61.
24. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179:1109-18.
25. Young JW, Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity [comment]. J Exp Med 1996;183:7-11.
26. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell I-associated cytokines [see comments]. J Exp Med 1996;183:87-97.
27. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD, Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity [see comments]. J Exp Med 1996;183:283-7.
28. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo [see comments]. J Exp Med 1996;183:317-22.
29. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-302.
30. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo [see comments]. J Exp Med 1996;183:317-22.
31. van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 1996; 156:3308-14.
32. + T cells. J Clin Invest 1994;94:797-807.
33. von Rohr A, Ghosh AK, Thatcher N, Stern PL. Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy. Br J Cancer 1993;67:163-71.
34. Rivoltini L, Loftus DJ, Barracchini K, et al. Binding and presentation of peptides derived from melanoma antigens MART-1 and gp100 by HLA-A2 subtypes: implications for peptide-based immunotherapy. J Immunol 1996;156:3882-91.
35. Krausa P, Brywka M, Savage D, et al. Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens 1995;45:223-31.
36. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994;91:3515-9.
37. Rivoltini L, Baracchini KC, Viggiano V, et al. Quantitative correlation between HLA Class I allele expression and recognition of melanoma cells by antigen specific cytotoxic T lymphocytes. Cancer Res 1995;55:3149-57.
38. Cerundolo V, Alexander J, Anderson K, et al. Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature 1990;345:449-52.
39. Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides [see comments]. Nature 1992;356:443-6.
40. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201 binding residues. J Immunol 1996;157:2539-48.
41. Marincola FM, Shamamian P, Alexander RB, et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994;153:1225-37.
42. Marincola FM, Hijazi YM, Fetsch P, et al. Analysis of expression of the melanoma associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother 1996;19:192-205.
43. O'Neil BH, Kawakami Y, Restifo NP, Bennink JR, Yewdell JW, Rosenberg SA. Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. J Immunol 1993;151:1410-8.
44. Wang XM, Terasaki PI, Rankin GW Jr, Chia D, Zhong HP, Hardy S. A new microcellular cytotoxicity test based on calcein AM release. Hum Immunol 1993;37:264-70.
45. Bakker AB, Marland G, de Boer AJ, et al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 1995;55:5330-4.
46. Kundig TM, Shahinian A, Kawai K, et al. Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity 1996;5:41-52.
47. Marincola FM, Rivoltini L, Salgaller ML, Player M, Rosenberg SA. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in vivo priming by tumor cells. J Immunother 1996;19:266-77.
48. + cytotoxic T lymphocytes. J Exp Med 1995;181: 363-8.
49. van Elsas A, van der Burg SH, van der Minne CE, Borghi M, Melief CJ, Schrier PI. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. Eur J Immunol 1996;26:1683-9.
50. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8.
51. Christinck ER, Luscher MA, Barber BH, Williams DB. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 1991;352:67-70.
52. Restifo NP. Recombinant anti-cancer vaccines. Cancer J Sci Am 1996;2:16-8.
53. Sheil JM, Bevan MJ, Lefrancois L. Characterization of dual-reactive H-2Kb-restricted anti-vesicular stomatitus virus and allo-reactive cytotoxic T cells. J Immunol 1987;138:3654-60.
54. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 1996;156:224-31.
55. McCabe BJ, Irvine KR, Nishimura MI, et al. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res 1995;55: 1741-7.
56. Bronte V, Tsung K, Rao JB, et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 1995;154:5282-92.
57. Wang M, Bronte V, Chen PW, et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 1995;154:4685-92.
58. Irvine KR, McCabe BJ, Rosenberg SA, Restifo NP. Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J Immunol 1995;154:4651-7.
59. Niedermann G, Butz S, Ihlenfeldt HG, et al. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity 1995;2:289-99.
60. Loftus DJ, Castelli C, Clay TM, et al. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J Exp Med 1996;184:647-57.
61. Schild H, Rotzschke O, Kalbacher H, Rammensee HG. Limit of T cell tolerance to self proteins by peptide presentation. Science 1990;247:1587-9.
62. Sheil JM, Shepherd SE, Klimo GF, Paterson Y. Identification of an autologous insulin B chain peptide as a target antigen for H-2Kb-restricted cytotoxic T lymphocytes. J Exp Med 1992;175:545-52.
63. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-9.
64. Houbiers JG, Nijman HW, van der Burg SH, et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993;23:2072-7.
65. Oukka M, Riche N, Kosmatopoulos K. A nonimmunodominant nucleoprotein-derived peptide is presented by influenza A virus-infected H-2b cells. J Immunol 1994;152:4843-51.